TY - JOUR
T1 - An Update and Review of the Treatment of Myoclonus
AU - Mills, Kelly
AU - Mari, Zoltan
N1 - Funding Information:
Zoltan Mari has received consultancy fees from Medtronic, Inc., US World Meds, and Ipsen. Dr. Mari has also received grants from the National Institutes of Health, the National Parkinson Foundation, the Michael J. Fox Foundation, Avid Radiopharmaceuticals, the Dystonia Medical Research Foundation, US World Meds, Solvay Pharmaceuticals Inc., Weill Medical College of Cornell University, and Merz Pharmaceuticals.
Publisher Copyright:
© 2014, Springer Science+Business Media New York.
PY - 2015/1
Y1 - 2015/1
N2 - Recent advances in medications and surgical therapy for neurological disorders may offer new therapeutic options for the treatment of myoclonus. Appropriate therapy for myoclonus depends on the etiology, and in some cases, myoclonus can improve when the provoking cause is eliminated. When the underlying cause for the movements is not immediately reversible, localization, disease pathophysiology, and etiology may each play a role in determining the most appropriate symptomatic treatment of disabling myoclonic jerks. While the use of many agents is still based on small, open-label case series and anecdotes, there is a growing body of evidence from head-to-head comparative trials in several types of myoclonus that may help guide therapy. New therapies for refractory myoclonus, including sodium oxybate and even deep brain stimulation, are also being explored with increasing enthusiasm.
AB - Recent advances in medications and surgical therapy for neurological disorders may offer new therapeutic options for the treatment of myoclonus. Appropriate therapy for myoclonus depends on the etiology, and in some cases, myoclonus can improve when the provoking cause is eliminated. When the underlying cause for the movements is not immediately reversible, localization, disease pathophysiology, and etiology may each play a role in determining the most appropriate symptomatic treatment of disabling myoclonic jerks. While the use of many agents is still based on small, open-label case series and anecdotes, there is a growing body of evidence from head-to-head comparative trials in several types of myoclonus that may help guide therapy. New therapies for refractory myoclonus, including sodium oxybate and even deep brain stimulation, are also being explored with increasing enthusiasm.
KW - Cortical myoclonus
KW - Cortical-subcortical myoclonus
KW - Deep brain stimulation
KW - Movement disorder
KW - Myoclonus treatment
KW - Myoclonus-dystonia
KW - Segmental myoclonus
KW - Subcortical-nonsegmental myoclonus
UR - http://www.scopus.com/inward/record.url?scp=84937210431&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937210431&partnerID=8YFLogxK
U2 - 10.1007/s11910-014-0512-2
DO - 10.1007/s11910-014-0512-2
M3 - Review article
C2 - 25398378
AN - SCOPUS:84937210431
SN - 1528-4042
VL - 15
JO - Current neurology and neuroscience reports
JF - Current neurology and neuroscience reports
IS - 1
ER -